Inventor · disambiguated record
Kalpana Shah
Also filed as: SHAH KALPANA
18 granted patents·7 pending applications·103 citations·filing 2014–2025
93Inventor score
Files withMACROGENICS INC25
Top patents by PatentIndex Score
25 records- 0195US11623959B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2020·Granted Apr 11, 2023·6 cites·23 claims
- 0295US10633440B2Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·11 cites·18 claims
- 0395US10577422B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 3, 2020·19 cites·10 claims
- 0495US10160806B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2015·Granted Dec 25, 2018·18 cites·34 claims
- 0594US10647768B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2015·Granted May 12, 2020·19 cites·21 claims
- 0693US11858991B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2021·Granted Jan 2, 2024·2 cites·18 claims
- 0789US11384149B2Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereofMACROGENICS INC·Filed 2019·Granted Jul 12, 2022·4 cites·13 claims
- 0888US11072653B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Jul 27, 2021·4 cites·17 claims
- 0988US10954301B2Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 23, 2021·3 cites·8 claims
- 1086US11098119B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2018·Granted Aug 24, 2021·2 cites·14 claims
- 1185US10501552B2Multivalent molecules comprising DR5-binding domainsMACROGENICS INC·Filed 2015·Granted Dec 10, 2019·6 cites·26 claims
- 1285US2024117036A1Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2023·Application pending·0 cites
- 1385US2024182559A1MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSMACROGENICS INC·Filed 2023·Application pending·0 cites
- 1484US11697684B2Tri-specific binding molecules that specifically bind to multiple cancer antigensMACROGENICS INC·Filed 2020·Granted Jul 11, 2023·1 cites·13 claims
- 1584US2025304685A1Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 1683US11820818B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2020·Granted Nov 21, 2023·1 cites·16 claims
- 1781US10344092B2Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereofMACROGENICS INC·Filed 2014·Granted Jul 9, 2019·5 cites·9 claims
- 1880US2024084015A1Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4MACROGENICS INC·Filed 2023·Application pending·0 cites
- 1976US9932400B2Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereofMACROGENICS INC·Filed 2014·Granted Apr 3, 2018·2 cites·20 claims
- 2074US2022041714A1Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use ThereofMACROGENICS INC·Filed 2021·Application pending·0 cites
- 2173US11840571B2Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4MACROGENICS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 2268US2022372144A1Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses ThereofMACROGENICS INC·Filed 2022·Application pending·0 cites
- 2362US10858430B2Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereofMACROGENICS INC·Filed 2017·Granted Dec 8, 2020·0 cites·20 claims
- 2454US12435155B2CD137 binding molecules and uses thereofMACROGENICS INC·Filed 2021·Granted Oct 7, 2025·0 cites·17 claims
- 2540US2019002563A1Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses ThereofMACROGENICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kalpana Shah files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →